Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5390778 | 0.90 | TACR1 (0.62) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5400644 | 0.89 | TACR1 (0.56) | TACR1CYP3A4CYP2D6CYP2C9SGMS1 | |
| SCHEMBL5394686 | 0.89 | TACR1 (0.44) | TACR1 | |
| SCHEMBL6261488 | 0.88 | TACR1 (0.61) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5398565 | 0.82 | TACR1 (0.52) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5389958 | 0.82 | TACR1 (0.52) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5386422 | 0.79 | TACR1 (0.49) | TACR1 | |
| SCHEMBL5398539 | 0.79 | TACR1 (0.49) | TACR1 | |
| SCHEMBL5390865 | 0.78 | TACR1 (0.50) | TACR1 | |
| SCHEMBL6264741 | 0.78 | TACR1 (0.67) | TACR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214680-B2 | 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | SLC6A4, TPH1, HTR1D | TACR1 49/4885CYP3A4 996/4885CYP2D6 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.